The rapid commercial maturation of the Neulasta Pegfilgrastim And Biosimilar Market highlights how competitive dynamics can completely redefine patient care access within oncology. Historically, the high costs associated with pegfilgrastim limited its preventative use to high-risk patients or wealthy nations, leaving many individuals exposed to severe chemotherapy-induced infections. Today, the...